Development of Effective Markers for Resistance of Oral Squamous Cell Carcinoma to Molecular-targeting Drugs

• Project/Area Number: 25463120
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Tokai University
• Principal Investigator: YAMAZAKI Hiroshi 東海大学, 医学部, 准教授 (00338708)
• Co-Investigator(Kenkyū-buntansha): MORI Taisuke 国立がん研究センター, 中央病院病理臨床検査部, 医員 (00296708)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: 外科系歯学 / 臨床腫瘍学 / 口腔癌 / 歯学 / 癌 / 遺伝子 / 口腔扁平上皮癌 / 分子標的薬 / 薬剤感受性試験

Outline of Final Research Achievements

The purpose of this study was to establish a method for estimating the efficacy of the molecular-targeting agent cetuximab (C-mab) for oral squamous cell carcinoma (OSCC). First, the sensitivity of OSCC cell lines and clinical specimens to C-mab was investigated. The sensitivity varied among cell lines, while 30% of the clinical specimens showed sensitivity. It has been reported that variations of the EGFR cause differences in sensitivity. Accordingly, surgical specimens were investigated for the expression of variant EGFR. As a result, the positivity rate was 100% and 12.5% for the wild-type and variant EGFR, respectively. These results suggest that there are other factors related to resistance in addition to EGFR variations.

Research Products

• [Journal Article] MRI analysis of chronological changes in free-flap volume in head and neck reconstruction by volumetry (2014)
  • Author(s): Yuki Sakamoto, Taro Takahara, Yoshihide Ota, Takayuki Aoki, Hiroshi Yamazaki, Mitsunobu Otsuru, Miho Takahashi, Ken-ichi Aoyama, Akihiro Kaneko, Shunichi Kawada, Tamaki Ichikawa, Kotaro Imagawa, Muneo Miyasaka
  • Journal Title: The Tokai Journal of Experimental and Clinical Medicine Volume: 39(1) Pages: 44-50
  • Peer Reviewed
• [Journal Article] Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis. (2013)
  • Author(s): Yamazaki H, Mori T, Yazawa M, Maeshima AM, Matsumoto F, Yoshimoto S, Ota Y, Kaneko A, Tsuda H, Kanai Y.
  • Journal Title: Lab Invest. Volume: Dec;93(12): Issue: 12 Pages: 1331-8
  • DOI: 10.1038/labinvest.2013.120
  • Peer Reviewed
• [Journal Article] 口腔扁平上皮癌術後ハイリスク群における3週毎シスプラチンを用いた化学放射線療法の検討 (2013)
  • Author(s): 大鶴光信 太田嘉英 青木隆幸 山﨑浩史 新井俊弘 鈴木崇嗣 傳田祐也 齋藤寛一 金子明寛
  • Journal Title: 日本口腔腫瘍学会雑誌 Volume: 25(1) Pages: 1-6
  • Peer Reviewed
• [Presentation] 口腔扁平上皮癌におけるEGFRvariantⅢの発現に関する検討 (2015)
  • Author(s): 山崎浩史
  • Organizer: 第６０回（公社）日本口腔外科学会総会・学術大会
  • Place of Presentation: 名古屋国際会議場（愛知県名古屋市）
  • Year and Date: 2015-10-16
• [Presentation] 当科におけるセツキシマブの使用経験 (2015)
  • Author(s): 山崎浩史 太田嘉英 青木隆幸 大鶴光信 加藤久視 鈴木崇嗣 青山謙一 関根理予 吉田佳史 内堀雅博 中西康大 金子明寛
  • Organizer: 第33回日本口腔腫瘍学会総会・学術大会
  • Place of Presentation: 奈良県奈良市
  • Year and Date: 2015-01-29 – 2015-01-30
• [Presentation] 当科におけるセツキシマブ使用経験 (2014)
  • Author(s): 山崎浩史 太田嘉英 青木隆幸 大鶴光信 新井俊弘 鈴木崇嗣 傳田祐也 齋藤寛一 大野啓介 金子明寛
  • Organizer: 第32回日本口腔腫瘍学会総会・学術大会
  • Place of Presentation: 北海道札幌市
• [Presentation] 当科におけるセツキシマブの使用経験 (2013)
  • Author(s): 山崎浩史 太田嘉英 青木隆幸 大鶴光信 新井俊弘 鈴木崇嗣 傳田祐也 齋藤寛一 大野啓介 金子明寛
  • Organizer: 第58回（公社）日本口腔外科学会総会・学術大会
  • Place of Presentation: 福岡県福岡市
• [Presentation] 当科におけるアービタックス（cetuximab）使用経験 (2013)
  • Author(s): 山崎浩史 太田嘉英 青木隆幸 大鶴光信 新井俊弘 鈴木崇嗣 傳田祐也 齋藤寛一 金子明寛
  • Organizer: 第67回NPO法人日本口腔科学会学術集会
  • Place of Presentation: 栃木県宇都宮市